Physician profile
Maximo B Lamarche
NPI 1003852567
$4,983.15
in general payments reported to CMS, 2019-2025
39 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $365 · 2021: $607 · 2022: $1,268 · 2023: $571 · 2024: $503 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $571.91 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Vifor Pharma, INC. | $556.18 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $529.01 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $466.14 | 2019-2025 | Farxiga |
| Gilead Sciences, INC. | $385.81 | 2022-2024 | |
| Philips North America LLC | $264.62 | 2019-2020 | |
| Amgen INC. | $223.99 | 2019-2024 | Tavneos |
| Mallinckrodt Hospital Products INC. | $212.56 | 2020-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $201.28 | 2022-2024 | Tarpeyo |
| Akebia Therapeutics INC | $181.30 | 2019-2021 | |
| Daiichi Sankyo INC. | $130.70 | 2019-2023 | Injectafer |
| Janssen Products, Lp | $116.42 | 2022 | |
| Merck Sharp & Dohme LLC | $106.08 | 2022-2025 | Pifeltro, Delstrigo |
| Bayer Healthcare Pharmaceuticals INC. | $105.74 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $104.20 | 2019-2025 | Abilify Asimtufii, Jynarque |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximo Lamarche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.